mRNA Vaccines: a Powerful Tool in Cancer Treatment
DOI:
https://doi.org/10.61173/enxv7x20Keywords:
mRNA vaccine, cancer immunotherapy, mRNA delivery, LNP, personalized vaccineAbstract
Cancer has always been one of the difficult objects for people to conquer. It’s killed a lot of people over a long period of time. As time goes on, technology becomes more and more advanced, and people are not limited to previous cancer treatments, but continue to research and try to find more treatments. In recent years, mRNA vaccines have gradually entered our field of vision. Compared with conventional vaccines, it often has a more flexible structure that can be modified, safer delivery methods, and higher efficiency. Although functional beyond imagination, the lack of knowledge in this area has prevented the use of mRNA vaccines in the treatment of many cancers. Once the many limitations and problems of mRNA are successfully solved, it can not only greatly promote the development of cancer treatment, but also make modern medicine get a milestone. This review introduces the current research and development progress of mRNA vaccines, and discusses the structure, delivery and application of mRNA vaccines.
References
[1] Zhang Y, Zhang Z. The history and advances in cancer Dean&Francis immunotherapy: understanding the characteristics of tumorinfiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020 Aug;17(8):807-821.
[2] Huang T, Peng L, Han Y, Wang D, He X, Wang J, Ou C. Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Front Immunol. 2022 Aug 26;13:922301.
[3] Lorentzen CL, Haanen JB, Met Ö, Svane IM. Clinical advances and ongoing trials on mRNA vaccines for cancer treatment. Lancet Oncol. 2022 Oct;23(10):e450-e458.
[4] Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu J, She Q, Tan J, Lou C, Liao Z, Li X. mRNA vaccine in cancer therapy: Current advance and future outlook. Clin Transl Med. 2023 Aug;13(8):e1384.
[5] Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021 Feb 25;20(1):41.
[6] Zhang G, Tang T, Chen Y, Huang X, Liang T. mRNA vaccines in disease prevention and treatment. Signal Transduct Target Ther. 2023 Sep 20;8(1):365.
[7] Liu J, Fu M, Wang M, Wan D, Wei Y, Wei X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. J Hematol Oncol. 2022 Mar 18;15(1):28.
[8] Xu S, Yang K, Li R, Zhang L. mRNA Vaccine Era- Mechanisms, Drug Platform and Clinical Prospection. Int J Mol Sci. 2020 Sep 9;21(18):6582.
[9] Kiaie SH, Majidi Zolbanin N, Ahmadi A, Bagherifar R, Valizadeh H, Kashanchi F, Jafari R. Recent advances in mRNA- LNP therapeutics: immunological and pharmacological aspects. J Nanobiotechnology. 2022 Jun 14;20(1):276.
[10] Cheng X, Lee RJ. The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery. Adv Drug Deliv Rev. 2016 Apr 1;99(Pt A):129-137.
[11] De Keersmaecker B, Claerhout S, Carrasco J, Bar I, Corthals J, Wilgenhof S, Neyns B, Thielemans K. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma. J Immunother Cancer. 2020 Feb;8(1):e000329.
[12] Guo Y, Lei K, Tang L. Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy. Front Immunol. 2018 Jul 2;9:1499.
[13] Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ, Jafferji MS, Prickett TD, Goff SL, McGowan CT, Seitter S, Shindorf ML, Parikh A, Chatani PD, Robbins PF, Rosenberg SA. mRNA vaccineinduced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020 Nov 2;130(11):5976- 5988.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
